Multiple myeloma (MM), for example, was considered broadly incurable, but with current immunotherapy interventions, the MM specific B cell maturation antigen (BCMA) has proved to be a good target for CAR T cell therapy and clinical safety and ability to produce a short-term objective response are encouraging and extending the time to remission [27]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.